As shown in Figure 3A, mice treated with G1T38 elicited 38% tumor regression after 21 days of treatment while control animals had a 577% increase in tumor burden over the same treatment period, demonstrating that G1T38 is highly efficacious in this HER2+ breast cancer model. This evidence concerns the gene ERBB2 and neoplasm.